araag2/HINT huggingface dataset:
Clinical trial NCT01992952 (phase 1/phase 2, status: active, not recruiting)
Conditions: estrogen receptor positive breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: azd5363, placebo, fulvestrant
SMILES: [H][C@@](CCO)(N=C(O)C1(N)CCN(CC1)C1=NC=NC2=C1C=CN2)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Post-menopausal Women

          -  Life expectancy 3 months

          -  Histological confirmation of ER+ breast cancer

          -  Clinical or histological confirmation of metastatic or locally advanced disease not
             amenable to surgical resection

          -  Measurable or non-measurable disease

          -  Adequate bone marrow, renal and hepatic function

          -  Eastern Cooperative Oncology Group (ECOG) performance status < or equal to 2

          -  Progressive disease whilst receiving an aromatase inhibitor (AI) for metastatic breast
             cancer (MBC)

          -  Relapsed with metastatic disease whilst receiving an AI in adjuvant setting

          -  Up to 3 prior lines of endocrine therapy for Advanced Breast Cancer

          -  Up to 1 line of chemotherapy for Advanced Breast Cancer

          -  Patient willing to donate archival tumour sample

          -  Patient willing to donate baseline blood sample

          -  Suitable for further endocrine therapy

        Exclusion Criteria:

          -  Previous treatment with fulvestrant or PI3K/mTOR(mammalian target of rapamycin )/Akt
             inhibitor therapy

          -  Treatment with chemotherapy, immunotherapy or targeted, biologic or tumour
             embolisation within 21 days of study drug administration

          -  Palliative radiotherapy within 7 days of study drug

          -  Clinically significant abnormalities in glucose metabolism

          -  Rapidly progressive visceral disease not suitable for further endocrine therapy

          -  Known brain or leptomeningeal metastases

          -  Any co-existing medical condition precluding trial entry including significant cardiac
             disease (to be defined in the protocol)

          -  Concomitant medication unsuitable for combination with trial medication
Clinical trial NCT02000700 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin 100 mg, canagliflozin 50 mg, canagliflozin 300 mg, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with Type 2 Diabetes Mellitus

          -  Be on a stable regimen of metformin immediate release (IR) monotherapy of at least
             1,000 mg/day for at least 8 weeks before screening

          -  Able to swallow whole tablets

          -  Absence of pancreatic autoimmunity

          -  Participants and their caregivers must agree to perform the fasting fingerstick
             glucose self-monitoring during the study

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus

          -  History of maturity onset diabetes of the young (MODY) and any secondary form of
             diabetes

          -  Current clinically significant medical illness e.g., significant pulmonary disease,
             renal or hepatic insufficiency, uncontrolled thyroid disease

          -  Systolic or diastolic blood pressure outside the range considered normal for the
             participant sex, age and height

          -  For females, participants will be excluded if pregnant
Clinical trial NCT02009488 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin, 100 mg, canagliflozin, 300 mg, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a diagnosis of T2DM for at least 3 months and be on either metformin
             monotherapy at a stable dose of >=1,000 mg per day or on combination therapy of
             metformin >=1,000 mg per day and a DPP-4 inhibitor at stable daily doses for at least
             12 weeks prior to screening with an HbA1c of >=7.0% and <= 9.5% at Screening

          -  Fasting plasma glucose >=120 mg/dL and <=240 mg/dL at the Week -4 visit

          -  Fasting fingerstick glucose >=120 mg/dL and <=240 mg/dL performed at clinical research
             center on Day -14

          -  Must be medically stable on the basis of clinical laboratory tests performed at
             screening

        Exclusion Criteria:

          -  Has a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or
             β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Has claustrophobia or anxiety, related to previous negative experiences with magnetic
             resonance imaging procedures which cannot be managed with an anxiolytic drug

          -  Has a history of brittle or labile glycemic control, with widely varying glucose
             measurements

          -  Has proliferative diabetic retinopathy (based on an eye examination within one year
             prior to Screening), currently receiving or requiring treatment

          -  Has a history of 1 or more severe hypoglycemic episodes within 6 months before
             screening

          -  Has history of hereditary glucose-galactose malabsorption or primary renal glucosuria.
Clinical trial NCT02013128 (phase 1/phase 2, status: completed)
Conditions: chronic lymphocytic leukemia, mantle cell lymphoma
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ublituximab, ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed Mantle Cell lymphoma (MCL) open for enrollment. The Chronic Lymphocytic
             Leukemia (CLL) enrollment arm is now closed.

          -  Refractory to or relapsed after at least 1 prior treatment regimen

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

        Exclusion Criteria:

          -  Any major surgery, chemotherapy or immunotherapy within the last 21 days

          -  Known hepatitis B virus, hepatitis C virus or HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Prior
             Allogeneic hematologic stem cell transplant is excluded.

          -  Richter's transformation, prolymphocytic leukemia or primary central nervous system
             lymphoma
Clinical trial NCT02013362 (phase 1/phase 2, status: completed)
Conditions: peripheral t-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pralatrexate injection
SMILES: NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese patients at least 20 years of age.

          -  Patients histologically diagnosed with peripheral T-cell lymphoma by pathological
             diagnosis of biopsied lesion.

          -  Relapsed or refractory patients with a treatment history of at least one regimen.

          -  Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in
             two perpendicular directions and greater than 1.5 cm in maximum diameter on computed
             tomography performed.

          -  Patients expected to survive for at least 3 months.

          -  ECOG PS 0-2.

          -  Patients with adequate hemopoietic efficacy, liver and kidney function.

          -  Patients from whom written consent has been obtained prior to study initiation.

        Exclusion Criteria:

          -  Patients who received a chemotherapy agent or a high dose of a systemic
             adrenocorticosteroid within 21 days prior to initial administration of the study drug.

          -  Patients who received radiation therapy, phototherapy, or electron beam therapy within
             21 days prior to initial administration of the study drug.

          -  Patients who received another study drug within 28 days prior to initial
             administration of the study drug.

          -  Patients who received antibody therapy within 100 days prior to initial administration
             of the study drug.

          -  Patients with a history of allogeneic hematopoietic stem cell transplantation. Or
             patients with a history of autologous hematopoietic stem cell transplantation within
             100 days prior to initial administration of the study drug.

          -  Patients with cerebral metastasis or central nervous system lesion or a past history.

          -  Patients with active multiple primary cancer. Or patients with a history of a
             malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.

          -  Patients with severe cardiovascular disease.

          -  Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological
             investigation. Or patients positive for either HBc antibody or HBs antibody, and
             showing DNA more than sensitivity in HBV-DNA assay.

          -  Patients positive for CMV antigen on immunological investigation.

          -  Patients with infectious disease requiring treatment consisting of intravenous
             administration of antibacterial agent, fungicide, or antiviral drug.

          -  Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have
             insufficient pulmonary function.
Clinical trial NCT02023424 (phase 1, status: unknown status)
Conditions: rett syndrome
ICD codes: F84.2
Drugs: glatiramer acetate (copaxone®)
SMILES: CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Females, age 6-15 years (inclusive).

          2. Patients whose parents or legal custodians have provided written informed consent to
             participate in the study.

          3. A diagnosis of RTT (classical or variant), defined according to the internationally
             agreed 2010 RetSearch criteria [4].

          4. Evidence of a genetically defined pathological change in the MECP2 gene (point
             mutation or deletion)

          5. Patients with known epileptiform activity as recorded on EEG.

          6. Blood pressure and heart rate within normal limits (blood pressure: systolic 90-140
             mmHg; diastolic 50-90 mmHg, heart rate 40-120 beats per minute

          7. An electrocardiogram (ECG) which, according to the Investigator's judgment does not
             contraindicate participation in the study.

          8. No clinically significant abnormalities in haematology, blood chemistry lab tests at
             screening.

          9. Parents must be able to understand the requirements of the study and must be willing
             to comply with the requirements of the study

        Exclusion Criteria:

          1. Any medical problem or chronic illness beyond those known to be associated with Rett
             Syndrome which, in the investigator's judgment, contraindicates administration of the
             study medication.

          2. Severe respiratory dysfunction (defined as tracheostomy and/or chronic oxygen therapy
             at least 4 hours a day and/or repeated aspiration pneumonia - at least 4 in the last
             year).

          3. Intractable seizures that started during the last 6 months prior to beginning of the
             study.

          4. Known hypersensitivity to glatiramer or mannitol.

          5. Participation in another clinical study.

          6. Parents of a patient who are unable to communicate well with the investigator and
             staff and comply with study procedures and follow-up

          7. Parents of a patient who are unwilling to sign consent form.
Clinical trial NCT02034071 (phase 1/phase 2, status: completed)
Conditions: prader-willi syndrome
ICD codes: Q87.11
Drugs: dccr, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children. adolescents and young adults with genetically confirmed Prader-Willi
             syndrome

          -  Ages at ≥ 10 years and ≤ 22 years

          -  Generally healthy as documented by the medical history, physical examination, vital
             sign assessments, 12-lead electrocardiogram (ECG), and clinical laboratory assessments

          -  BMI exceeds the 95th percentile of the age specific BMI value on the CDC BMI charts

          -  Fasting glucose ≤ 126 mg/dL

          -  HbA1c ≤ 6.5 %

        Exclusion Criteria:

          -  Administration of investigational drugs within 1 month prior to Screening Visit

          -  Anticipated requirement for use of prohibited medications

          -  History of allergic reaction or significant intolerance to: diazoxide, thiazides or
             sulfonamides

          -  Anticipate transitions in their care from family home to group home or other similar
             potentially disruptive changes

          -  Congestive heart failure or known compromised cardiac reserve

          -  Any other clinically significant endocrine, cardiovascular, pulmonary, neurological,
             psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological
             disease interfering with the assessments of the investigational drug, according to the
             Investigator
Clinical trial NCT02037165 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: placebo to bi 1026706, pregabalin, bi 1026706, celecoxib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion criteria:

          1. Healthy males according to the investigator's assessment, as based on the following
             criteria: a complete medical history including a physical examination, vital signs
             (Blood Pressure, Pulse Rate), 12-lead electrocardiogram, and clinical laboratory

          2. Age 18 to 55 years (incl.)

          3. BMI (Body Mass Index) 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          1. Any finding in the medical examination (including Blood Pressure, Pulse Rate or
             Electrocardiogram) deviating from normal and judged clinically relevant by the
             investigator

          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic
             blood pressure greater than 90 mm Hg

          3. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          4. Any evidence of a concomitant disease judged clinically relevant by the investigator

          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)

          7. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
Clinical trial NCT02037230 (phase 1/phase 2, status: completed)
Conditions: adenocarcinoma of the pancreas
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: mk-1775, gemcitabine
SMILES: CN1CCN(CC1)C1=CC=C(NC2=NC=C3C(=O)N(CC=C)N(C3=N2)C2=NC(=CC=C2)C(C)(C)O)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have pathologically confirmed adenocarcinoma of the pancreas.

          -  Patients will have unresectable disease, defined radiographically as >180 degrees
             involvement of the superior mesenteric artery or celiac trunk or SMV/portal vein
             impingement that cannot be surgically reconstructed, in the absence of distant
             metastasis..

          -  Patients must have a Zubrod performance status (measure of general well being that
             ranges from 0 to 5 where 0 represents perfect health) of < 2.

          -  Patients must have adequate organ function defined as follows: absolute neutrophil
             count of ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum creatinine ≤ 2 mg/dl, total
             bilirubin ≤ 3, (with relief of biliary obstruction if present (PTC tube or endobiliary
             stent)) and AST < 5 times the upper limit of normal.

          -  Patients of reproductive potential must agree to use an effective contraceptive method
             during participation in this trial and for 6 months after the trial. Patients must not
             be breastfeeding.

          -  Patients must be aware of the investigational nature of the therapy and provide
             written informed consent.

          -  Patients must be at least 18 years old.

        Exclusion Criteria:

          -  Other serious uncontrolled concomitant systemic disorders or psychiatric condition
             that would interfere with the safe delivery of protocol therapy.

          -  A history of previous chemotherapy for pancreatic cancer or abdominal radiation
             therapy.

          -  The use of any investigational agent in the month before enrollment into the study.

          -  Inability to discontinue a prescription or non-prescription drugs or other products
             known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 prior to Day 1 of
             dosing and to withhold throughout the study until 2 weeks after the last dose of study
             medication. Medications of particular concern are the following inhibitors of CYP3A4:
             azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole), macrolide
             antibiotics (erythromycin, clarithromycin), cimetidine, aprepitant, HIV protease
             inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin, barbiturates
             and rifampicin. Substrates of CYP3A4 include statins (lovastatin, simvastatin),
             midazolam, terfenadine, astemizole, and cisapride.
Clinical trial NCT02040870 (phase 1/phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ldk378
SMILES: CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1
Eligibility criteria:

        Inclusion criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK
             rearrangement defined as positive using the FDA approved Vysis ALK Break Apart FISH
             Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity
             criteria) or positive as assessed by the CFDA approved immunohistochemistry (IHC) test
             (Ventana Medical Systems, Inc)

          -  Age 18 years or older at the time of informed consent.

          -  Patients must have stage IIIB or IV NSCLC at the time of study entry and have had
             progressive disease during or after crizotinib treatment whether or not previously
             treated with cytotoxic chemotherapy. If treated with chemotherapy, maximum 2 lines are
             allowed.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the excipients of LDK378

          -  Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or have required increasing doses of steroids within the 2
             weeks prior to study entry to manage CNS symptoms

          -  History of carcinomatous meningitis

          -  Presence or history of a malignant disease other than NSCLC that has been diagnosed
             and/or required therapy within the past 3 years.

          -  clinically significant, uncontrolled heart disease.
Clinical trial NCT02043860 (phase 1, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: melphalan, filgrastim (g-csf)
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients meeting criteria for symptomatic myeloma

          2. Patients must be high or intermediate risk of disease progression as defined by having
             one of the following criteria: 2.1 ISS stage 2 or 3 disease 2.2 Abnormal metaphase
             cytogenetics 2.3 Presence of FISH abnormalities aside from hyperdiploidy

          3. Patients who have received at least 2 cycles of systemic treatment of any kind in the
             preceding 12 months

          4. Patient age 18-75 years at time of enrollment

          5. Karnofsky performance status of ≥70

          6. Cardiac function: LVEF >40%

          7. Hepatic: Bilirubin <2x upper limit of normal and ALT and AST < 2.5x the upper limit of
             normal

          8. Renal: Creatinine clearance of ≥30mL/min, estimated or calculated

          9. Pulmonary: DLCO, FEV1, FVC >50% of predicted (after correction for hemoglobin)

        Exclusion Criteria:

          1. Patients with diagnosis of plasma cell leukemia

          2. Patients with myeloma who have had any disease progression prior to enrollment

          3. Patients with truly non secretory myeloma (patients with light chain disease are
             eligible)

          4. Pregnant or breast-feeding

          5. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if
             there is evidence of response to medication. Eligibility of HIV infected patients will
             be determined on a case-by-case basis.

          6. Patients who have undergone prior allograft or autologous transplant

          7. Prior solid organ transplant

          8. Patients receiving prior radiation to more than 20% of bone marrow containing areas